ICON Public (NASDAQ:ICLR) issued its quarterly earnings data on Tuesday. The medical research company reported $2.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.10 by $0.02, MarketWatch Earnings reports. The firm had revenue of $871.16 million during the quarter, compared to analysts’ expectations of $857.30 million. ICON Public had a net margin of 11.49% and a return on equity of 20.70%. ICON Public’s revenue for the quarter was up 40.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.20 earnings per share.
NASDAQ:ICLR traded down $4.57 during mid-day trading on Thursday, hitting $209.50. The company’s stock had a trading volume of 23,666 shares, compared to its average volume of 1,494,241. ICON Public has a fifty-two week low of $168.76 and a fifty-two week high of $234.22. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. The firm has a market cap of $11.23 billion, a P/E ratio of 33.16, a price-to-earnings-growth ratio of 2.01 and a beta of 0.84. The company has a fifty day simple moving average of $218.10.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of ICON Public from a “hold” rating to a “buy” rating and set a $232.00 price target for the company in a report on Thursday, July 1st. Citigroup assumed coverage on shares of ICON Public in a report on Wednesday, July 14th. They set a “neutral” rating and a $220.00 price target for the company. Wells Fargo & Company upgraded shares of ICON Public from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $200.00 to $235.00 in a report on Thursday, April 1st. Jefferies Financial Group upped their price target on shares of ICON Public from $256.00 to $267.00 and gave the company a “buy” rating in a report on Thursday, April 29th. Finally, Credit Suisse Group upped their price target on shares of ICON Public from $245.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. ICON Public presently has a consensus rating of “Buy” and an average price target of $234.64.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More: Quiet Period Expirations
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.